Catalyst Pharmaceuticals (CPRX) Work In Process (2023 - 2026)

Catalyst Pharmaceuticals has reported Work In Process for 4 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process fell 34.42% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 34.42% YoY), and the FY2025 full-year result was $3.9 million, up 12.37% from the prior year.
• Work In Process for Q1 2026 stood at $2.8 million, down from $3.9 million in the prior quarter.
• The five-year high for Work In Process was $5.3 million in Q2 2025, with the low at $2.8 million in Q1 2026.
• Historically, Work In Process has averaged $4.1 million across 4 years, with a median of $4.0 million in 2024.
• Annual changes were most pronounced in 2025 — Work In Process surged 32.89% — and 2026, when it sank 34.42%.
• Catalyst Pharmaceuticals' Work In Process stood at $4.6 million in 2023, then retreated by 24.67% to $3.4 million in 2024, then climbed by 12.37% to $3.9 million in 2025, then declined by 28.44% to $2.8 million in 2026.
• The last three Work In Process figures came in at $2.8 million (Q1 2026), $3.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.